Stockerstrasse 47, 8002 Zürich, Switzerland
BioXpress Therapeutics SA is exclusively focused on the development of biosimilars. With a philosophy that everyone should have access to high quality biologic therapeutics, BioXpress brings speed, efficiency and safety in developing biosimilar mAbs that impact patients’ quality of life.
Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).
Hengrui Europe Biosciences is a biotech start-up based in Zurich, Switzerland, established in 2021. We are a subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. and are building a new research center with a differentiated technology platform to support innovative antibody discovery research.